Alixorexton (ALKS 2680)
Narcolepsy Type 1
Key Facts
About Alkermes
Alkermes is a global biopharmaceutical leader focused on developing medicines for complex psychiatric and neurological disorders, leveraging deep neuroscience expertise. Its strategy integrates discovery, development, manufacturing, and commercialization, with a current pipeline anchored by late-stage candidates in sleep disorders and serious mental illness. Recent achievements include the initiation of Phase 3 studies for alixorexton in narcolepsy and the completion of the Avadel Pharmaceuticals acquisition, solidifying its position in sleep medicine.
View full company profileAbout Alkermes
Alkermes is a global biopharmaceutical leader focused on developing medicines for complex psychiatric and neurological disorders, leveraging deep neuroscience expertise. Its strategy integrates discovery, development, manufacturing, and commercialization, with a current pipeline anchored by late-stage candidates in sleep disorders and serious mental illness. Recent achievements include the initiation of Phase 3 studies for alixorexton in narcolepsy and the completion of the Avadel Pharmaceuticals acquisition, solidifying its position in sleep medicine.
View full company profileAbout Alkermes
Alkermes is a global biopharmaceutical leader focused on developing medicines for complex psychiatric and neurological disorders, leveraging deep neuroscience expertise. Its strategy integrates discovery, development, manufacturing, and commercialization, with a current pipeline anchored by late-stage candidates in sleep disorders and serious mental illness. Recent achievements include the initiation of Phase 3 studies for alixorexton in narcolepsy and the completion of the Avadel Pharmaceuticals acquisition, solidifying its position in sleep medicine.
View full company profile